These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 6974592)
1. Differences in the pharmacokinetics of the diastereoisomers of citrovorum factor in dogs. Straw JA; Covey JM; Szapary D Cancer Res; 1981 Oct; 41(10):3936-9. PubMed ID: 6974592 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Straw JA; Szapary D; Wynn WT Cancer Res; 1984 Jul; 44(7):3114-9. PubMed ID: 6609768 [TBL] [Abstract][Full Text] [Related]
3. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion. Straw JA; Newman EM; Doroshow JH NCI Monogr; 1987; (5):41-5. PubMed ID: 3501545 [TBL] [Abstract][Full Text] [Related]
5. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer. Lacreta FP; Brennan JM; Hamilton TC; Ozols RF; O'Dwyer PJ Drug Metab Dispos; 1994; 22(6):835-42. PubMed ID: 7895599 [TBL] [Abstract][Full Text] [Related]
6. Human pharmacology of the methamphetamine stereoisomers. Mendelson J; Uemura N; Harris D; Nath RP; Fernandez E; Jacob P; Everhart ET; Jones RT Clin Pharmacol Ther; 2006 Oct; 80(4):403-20. PubMed ID: 17015058 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human. Timchalk C; Nolan RJ Toxicol Appl Pharmacol; 1997 Jun; 144(2):268-78. PubMed ID: 9194410 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacologic effects of the S(-) isomer of bupivacaine after intravenous and epidural administration in dogs. Franquelo C; Toledo A; Manubens J; Valladares JE; Cristòfol C; Arboix M Am J Vet Res; 1999 Jul; 60(7):832-5. PubMed ID: 10407475 [TBL] [Abstract][Full Text] [Related]
9. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947 [TBL] [Abstract][Full Text] [Related]
10. [l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate]. Etienne MC; Thyss A; Bertrand Y; Rubie H; Milano G Bull Cancer; 1993 Apr; 80(4):357-63. PubMed ID: 8173189 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the enantiomers of verapamil in the dog. Bai SA; Lankford SM; Johnson LM Chirality; 1993; 5(6):436-42. PubMed ID: 8398603 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600 [TBL] [Abstract][Full Text] [Related]
14. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Perucca E; Cloyd J; Critchley D; Fuseau E Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564 [TBL] [Abstract][Full Text] [Related]
15. Comparative inter-species pharmacokinetics of phenoxyacetic acid herbicides and related organic acids. evidence that the dog is not a relevant species for evaluation of human health risk. Timchalk C Toxicology; 2004 Jul; 200(1):1-19. PubMed ID: 15158559 [TBL] [Abstract][Full Text] [Related]
16. [Suitability of the peroral administration of the marker creatinine for the quantitative determination of the glomerular filtration rate (GFR) in dogs]. Hartmann H; Baumgardt T; Höchel J Berl Munch Tierarztl Wochenschr; 2006; 119(1-2):62-7. PubMed ID: 16450711 [TBL] [Abstract][Full Text] [Related]
17. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine. Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467 [TBL] [Abstract][Full Text] [Related]
18. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics. Prueksaritanont T; Gorham LM; Naue JA; Hamill TG; Askew BC; Vyas KP Drug Metab Dispos; 1997 Mar; 25(3):355-61. PubMed ID: 9172954 [TBL] [Abstract][Full Text] [Related]
19. Dexamethasone pharmacokinetics in clinically normal dogs during low- and high-dose dexamethasone suppression testing. Greco DS; Brown SA; Gauze JJ; Weise DW; Buck JM Am J Vet Res; 1993 Apr; 54(4):580-5. PubMed ID: 8387253 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs. Guedes AG; Papich MG; Rude EP; Rider MA J Vet Pharmacol Ther; 2008 Aug; 31(4):334-43. PubMed ID: 18638294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]